Rani Therapeutics Holdings Inc (NASDAQ:RANI) shares, rose in value on Thursday, April 16, with the stock price up by 1.74% to the previous day’s close as strong demand from buyers drove the stock to $1.17.
Actively observing the price movement in the last trading, the stock closed the session at $1.15, falling within a range of $1.11 and $1.2. The value of beta (5-year monthly) was 0.24. Referring to stock’s 52-week performance, its high was $8.75, and the low was $1.03. On the whole, RANI has fluctuated by -20.41% over the past month.
With the market capitalization of Rani Therapeutics Holdings Inc currently standing at about $67.25 million, investors are eagerly awaiting this quarter’s results, scheduled for on 2025-Mar-30.
Technical indicators serve as essential tools for traders, offering insights into market sentiment and potential price movements. We see that RANI’s technical picture suggests that short-term indicators denote the stock is a 100% Sell on average. However, medium-term indicators have put the stock in the category of 100% Sell while long-term indicators on average have been pointing out that it is a 100% Sell.
The stock’s technical analysis shows that the price of RANI currently trading nearly -8.24% and -19.13% away from the simple moving averages for 20 and 50 days respectively. The Relative Strength Index (RSI, 14) currently indicates a reading of 42.51, while the 7-day volatility ratio is showing 6.15% which for the 30-day chart, stands at 8.97%. Furthermore, Rani Therapeutics Holdings Inc (RANI)’s beta value is 0.28, and its average true range (ATR) is 0.11.
A comparison of Rani Therapeutics Holdings Inc (RANI) with its peers suggests the former has fared considerably weaker in the market. RANI showed an intraday change of 1.74% in last session, and over the past year, it shrunk by -82.97%%.
Data on historical trading for Rani Therapeutics Holdings Inc (NASDAQ:RANI) indicates that the trading volumes over the past 10 days have averaged 0.15 and over the past 3 months, they’ve averaged 854.58K. According to company’s latest data on outstanding shares, there are 33.43 million shares outstanding.
Nearly 32.12% of Rani Therapeutics Holdings Inc’s shares belong to company insiders and institutional investors own 7.99% of the company’s shares. The data on short interest also indicates that stock shorts accounted for 2.4 million shares as on 2025-03-31, resulting in a short ratio of 14.57. According to the data, the short interest in Rani Therapeutics Holdings Inc (RANI) stood at 1178.00 of shares outstanding as of 2025-03-31; the number of short shares registered in 2025-02-28 reached 2.47 million. The stock has fallen by -14.60% since the beginning of the year, thereby showing the potential of a further growth. This could raise investors’ confidence to be optimistic about the RANI stock heading into the next quarter.
